Physician profile
Seth Hepner
NPI 1609131663
$284,953.40
in general payments reported to CMS, 2019-2025
33 companies · $35K in 2025
The $35K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,683 · 2020: $25K · 2021: $124K · 2022: $64K · 2023: $18K · 2024: $17K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Food and Beverage: $5,604 · Travel and Lodging: $2,447 · Consulting Fee: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,781.25 |
| Food and Beverage | $5,603.98 |
| Travel and Lodging | $2,447.10 |
| Consulting Fee | $1,525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $197,314.81 | 2021-2025 | |
| Allergan, INC. | $38,863.96 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $18,287.00 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13,375.71 | 2022 | |
| Pfizer INC. | $12,845.85 | 2023-2025 | |
| Mdd US Operations, LLC | $713.88 | 2020-2023 | Apokyn, Gocovri |
| Neurocrine Biosciences, INC. | $483.40 | 2023-2025 | Ingrezza |
| Sk Life Science, INC. | $374.86 | 2020-2025 | Xcopri |
| Biogen, INC. | $306.77 | 2019-2023 | Vumerity |
| Eisai INC. | $241.80 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $240.90 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $186.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $126.63 | 2024 | Zeposia |
| Greenwich Biosciences, INC. | $126.21 | 2019 | |
| Genentech USA, INC. | $125.00 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $124.99 | 2019 | |
| Alexion Pharmaceuticals, INC. | $122.68 | 2019 | |
| Adamas Pharmaceuticals, INC. | $121.64 | 2020 | |
| Amgen INC. | $120.53 | 2019 | |
| Jazz Pharmaceuticals INC. | $117.79 | 2024 | |
| Celgene Corporation | $115.58 | 2021 | |
| Lundbeck LLC | $113.37 | 2020-2025 | Vyepti |
| Neurelis, INC. | $105.43 | 2023 | Valtoco |
| Averitas Pharma INC. | $105.40 | 2023 | Qutenza |
| Lilly USA, LLC | $68.62 | 2022-2023 | Emgality, Reyvow |
| Upsher-Smith Laboratories LLC | $50.90 | 2021 | |
| Argenx US, INC. | $49.73 | 2024 | Vyvgart |
| Emd Serono, INC. | $28.83 | 2019 | |
| Merz North America, INC. | $27.08 | 2019 | |
| Bausch Health US, LLC | $23.43 | 2019 | |
| Axsome Therapeutics, INC. | $18.03 | 2025 | Symbravo |
| Medtronic, INC. | $13.48 | 2022 | |
| Assertio Therapeutics, INC. | $12.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Hepner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.